Bile duct malignancies

Klinicka Onkologie

Volumn 23, Issue 4, 2010, Pages 231-241

  Tuček, Štěpán ^a,b   Tomasek J ^a,b   Halamkova J ^a   Kiss, I ^a,b   Andrasina T ^a   Hemmelova B ^a   Adamkova Krakorova D ^b   Vyzula, R ^a,b  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Bile duct neoplasms; Cholangiocarcinoma; Gallbladder cancer; Palliative treatment

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; STAT3 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR INHIBITOR;

APOPTOSIS; BARE METAL STENT; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILIARY TRACT ENDOSCOPY; BILIARY TRACT EXAMINATION; BILIARY TRACT SURGERY; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CHEMOEMBOLIZATION; CHOLANGIOGRAPHY; CHOLECYSTECTOMY; CHRONIC PANCREATITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CRYOABLATION; CZECH REPUBLIC; DIAGNOSTIC IMAGING; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; EXTRAHEPATIC CHOLANGIOCARCINOMA; GALLBLADDER CARCINOMA; HUMAN; INTRAHEPATIC CHOLANGIOCARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; MEDICAL CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTICAL COHERENCE TOMOGRAPHY; OVERALL SURVIVAL; PANCREAS CANCER; PATHOGENESIS; PERCUTANEOUS TRANSHEPATAL CATHETERIZATION; PERCUTANEOUS TRANSHEPATAL DRAINAGE; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; QUALITY OF LIFE; RADIOFREQUENCY ABLATION; REVIEW; TUMOR SUPPRESSOR GENE; VATER PAPILLA CARCINOMA; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMMON BILE DUCT NEOPLASMS; GALLBLADDER NEOPLASMS;

BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; COMMON BILE DUCT NEOPLASMS; GALLBLADDER NEOPLASMS; HUMANS; PROGNOSIS;

EID: 77956071706     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 1995; 75 (Suppl 1): 171-190.
2. Jarnagin W Cholangiocarcinoma of the extrahepatic bile ducts. Sem Surg Oncol 2000; 19(2): 156-176.
3. Cancer Incidence in the Czech Republic 2006 [pdf file]. Available from: www.uzis.cz.
4. Wotke J, Foukal T. Korelace klinické bioptické diagnózy karcinomu žlučníku. Klin Onkol 1994, 7(4): 117-119.
5. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2: 10.
6. Holzinger F, Z'graggen K, Buchler MW. Mechanisms of biliary carcinogenesis: A pathogenetic multi-stage cascade towards cholangiocarcinoma. Ann Oncol 1999; 10 (Suppl 4): 122-126.
7. Park J, Tadlock L, Gores GJ et al. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999; 30: 1128-1133. (Pubitemid 29510848)
8. Que FG, Phan VA, Phan VH et al. Cholangiocarcinomas express Fas ligand and disable the Fas receptor Hepatology 1999; 30. 1398-1404.
9. Yee K, Sheppard BC, Domreis J et al. Cancers of the gallbladder and biliary ducts. Oncology (Williston Park) 2002; 16(7): 939-946, 949.
10. Sandhu DS, Roberts LR. Diagnosis and management of cholangiocarcinoma. Curr Gastroenterol Rep 2008; 10(1): 43-52.
11. Parkin DM, Ohshima H, Srivatanakul P et al. Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention. Cancer Epidemiol Biomarkers Prev 1993; 2(6): 537-544.
12. Klener P et al. Klinická ontologie. Praha: Galén 2002. 421-422.
13. Yamamoto S, Kubo S, Hai S et al. Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci 2004, 95(7): 592-595. (Pubitemid 39089641)
14. Dutta U, Garg PK, Kumar R Typhoid carriers among patients with gallstones are at increased risk for carcinoma of the gallbladder. Am J Gastroenterol 2000; 95(3): 784-787. (Pubitemid 30123920)
15. de Bree E, Tsiftsis DD, Santos RM et al. Objective assessment of the contribution of each diagnostic test and of the ordering sequence in jaundice caused by pancreatobiliary carcinoma. Scand J Gastroenterol 2000; 35(4): 438-445.
16. Broden G, Bengtsson L. Biliary carcinoma associated with methyldopa therapy. Acta Chir Scand 1980; 500: 7.
17. Ellis EF, Gordon PR, Gottlieb LS. Oral contraceptives and cholangiocarcinoma. Lancet 1978; 1(8057): 207.
18. Lowenfels AB, Norman J. Isoniazid and bile duct cancer. JAMA 1978; 240(5): 434-435.
19. Mancuso TF, Brennan MJ Epidemiological considerations of cancer of the gallbladder, bile ducts and salivary glands in the rubber industry J Occup Med 1970; 12(9): 333-341.
20. Kowalewski K, Todd EF. Carcinoma of the gallbladder induced in hamsters by insertion of cholesterol pellets and feeding dimethylnitrosamine. Proc Soc Exp Biol Med 1971; 136(2) 482-486.
21. Harder J, Blum HE. Cholangiocarcinoma. Schweiz Rundsch Med Prax 2002; 91(34): 1352-1356.
22. Epidemiology of malignant tumours in the Czech Republic [website]. [Cited Sept 15, 2009]. Available from: www.svod.cz.
23. Fleming J, Cooper J, Henson D et al (eds). Gallbladder and extrahepatic bile ducts. AJCC Cancer Staging Handbook. Philadelphia: Lippincott-Raven 1998; 97-106.
24. Nakeeb A, Pitt HA, Sohn TA et al. Cholangiocarcinoma: a spectrum of intrahepatic perihilar, and distal tumours. Ann Surg 1996; 224(4): 463-473.
25. Válek V, Kala Z, Kiss I. Úskalí v diagnostice a léčbě onemocnění HPB. Zobrazovací vyšetření - senzitivita a specificita. Edukač ní sborník XXVIII Brněnské onkologické dny. Brno 2004: 162-166.
26. Hann LE, Greatrex KV, Bach AM et al. Cholangiocarcinoma at the hepatic hilus: sonographic findings. Am J Roentgenol 1997; 168(4): 985-989.
27. Bach AM, Hann LE, Brown KT et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial protography Radiology 1996; 201(1): 149-154.
28. Bohatá Š. Přínos kontrastního ultrazvukového vyšetření v diferenciá lní diagnostice ložiskových procesů jater. Doktorandská dizertační práce Brno LF MU 2009.
29. Loyer EM, Chin H, DuBrow RA et al. Hepatocellular carcinoma and intrahepatic peripheral cholangiocarcinoma: enhancement patterns with quadruple phase helical CT - a comparative study. Radiology 1999, 212(3): 866-875. (Pubitemid 29410995)
30. Lopera JE, Soto JA, Múnera F. Malignant Hilar and Perihilar Biliary Obstruction: Use of MR cholangiography to define the extent of biliary ductal involvement and plan percutaneous interventions. Radiology 2001; 220: 90-96. (Pubitemid 32577965)
31. Campbell WL, Ferris JV, Holbert BL et al. Biliary tract carcinoma complicating primary sclerosing cholangitis: Evaluation with CT, cholangiography, US, and MR imaging. Radiology 1998; 207(1): 41-50.
32. Hochwald SN, Burke EC, Jarnagin WR et al. Association of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinoma. Arch Surg 1998, 134(3): 261-266.
33. Otto G, Romaneehsen B, Hoppe-Lotichius M et al. Hilar cholangiocarcinoma: resectability and radicality after routine diagnostic imaging. J Hepatobiliary Pancreat Surg 2004, 11(5). 310-318. (Pubitemid 39485632)
34. Torok N, Gores GJ. Cholangiocarcinoma. Semin Gastrointest Dis 2001; 12(2): 125-132.
35. Van Beers BE. Diagnosis of cholangiocarcinoma. Oxford: HPB 2008; 10(2). 87-93.
36. Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45(1): 43-50. Epub 2006 Apr 19.
37. Kluge R, Schmidt F, Caca K et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer Hepatology 2001; 33(5): 1029-1035.
38. Carr TG, Kazarian KK, Smego DR et al. Radionuclide cholescintigraphy in patients with suspected biliary tract obstruction. Am Surg 1991; 57(10): 673-675.
39. Poneros JM, Tearney GJ, Shiskov M et al. Optical coherence tomography of the biliary tree during ERCP. Gastrointest Endosc 2002; 55(1): 84-88. (Pubitemid 41122934)
40. Singh P, Chak A, Willis JE et al. In vivo optical coherence tomography imaging of the pancreatic and biliary ductal system. Gastrointest Endosc 2005; 62(6): 970-974.
41. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl 2000; 6(6 Suppl 2): 30-34
42. Huang JL, Biehl TR, Lee FT et al. Outcomes after resection of cholangiocellular carcinoma. Am J Surg 2004; 187(5): 612-617.
43. Shimada M, Takenaka K, Kawahara N et al. Chemosensitivity in primary liver cancers: evaluation of the correlation between chemosensitivity and clinicopathological factors. Hepatogastroenterology 1996; 43(11): 1159-1164. (Pubitemid 26358508)
44. Marrelli D, Caruso S, Pedrazzani C et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg 2009; 198(3): 333-339. Epub 2009 Apr 17.
45. Bedi MM, Gandhi MD, Jacob G et al. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 2009; 28(1): 24-27. Epub 2009 Jun 6.
46. Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15(34): 4240-4262.
47. Tompkins RK, Thomas D, Wile A et al. Prognostic factors in bile duct carcinoma. Analysis of 96 cases. Ann Surg 1981; 194(4): 447-457.
48. Wade TP, Prasad CN, Virgo KS et al. Experience with distal bile duct cancers in U.S. Veterans Affairs hospitals: 1987-1991. J Surg Oncol 1997; 64(3): 242-245.
49. Okuda K, Kubo Y, Okazaki N et al. Clinical aspects of intrahepatic bile duct carcinoma including hilar carcinoma. A study of 57 autopsy-proven cases. Cancer 1977; 39(1): 232-246.
50. Sato S, Seitzinger GL, Garside E. Carcinoma of the extrahepatic bile ducts. Review of the literature and report of six cases. Surgery 1957; 41 (37): 416-437.
51. Burke EC, Jarnagin WR, Hochwald SN et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 1998; 228(3): 385-394
52. Donohue JH, Stewart AK, Menck HR. The national Cancer Data Base report on carcinoma of the gallbladder, 1989-1995. Cancer 1998; 83(12): 2618-2628.
53. Duffy A, Capanu M, Abou-Alfa GK et al. Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC). J Surg Oncol 2008, 98(7): 485-489.
54. DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer, Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins Publishers 2004; CD-ROM Chapter 29. Sec 5.
55. Jemal A, Tiwari RC, MurrayTet al. American Cancer Society. Cancer statistics, 2004 CA Cancer J Clin 2004; 54(1): 8-29.
56. Fong Y, Kemeny N, Lawrence TS. Cancer of the Liver and Biliary Tree. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds). Cancer, Principles & Practice of Oncology 6th ed Philadelphia Lippincott Williams and Wilkins Publishers 2001: 1162-1203.
57. De Aretxabala X, Roa I, Araya JC et al. Gallbladder cancer in Chile. A report on 54 potentially resectable tumors. Cancer 1992, 69(1): 60-65.
58. De Groen PC, Gores GJ, LaRusso NF et al. Biliary Tract Cancers. N Engl J Med 1999, 341(18): 1368-1378.
59. De Vita VT Jr, Hellman S, Rosenberg SA (eds). Cancer, Principles & Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins Publishers 2005: 1021.
60. Choi CW, Choi IK, Seo JH et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol 2000; 23(4): 425-428.
61. Chen H, Hardacre JM, Uzar A et al. Isolated liver metastases from neuroendocrine tumours: does resection prolong survival? J Am Coll Surg 1998; 187(1): 88-92 (Pubitemid 28303537)
62. Bucher P, Chassot G, Durmishi Y et al. Long-term results of surgical treatment of Vater's ampulla neoplasms. Hepatogastroenterology 2007; 54(76): 1239-1242. (Pubitemid 47013943)
63. Shirabe K, Shimada M, Harimoto N et al. Intrahepatic cholangiocarcinoma: its mode of spreading and therapeutic modalities. Surgery 2002; 131(1 Suppl): 159-164.
64. Fong Y, Blumgart LH, Lin E et al. Outcome of treatment for distal bile duct cancer. Br J Surg 1996; 83(12): 1712-1715.
65. Novotný J et al. C24 Zhoubný novotvar jiných a neurčených částí žlučový ch cest [website]. [cited June 6,2009]. Available from www.koc.cz.
66. Li S, Jo YS, Lee JH et al. L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res 2009, 15(23): 7345-7351. Epub 2009 Nov 17.
67. Karamitopoulou E, Tornillo L, Zlobec I et al. Clinical significance of cell cycle - and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas. Am J Clin Pathol 2008; 130(5): 780-786.
68. Alvaro D. Serum and bile biomarkers for cholangiocarcinoma. Curr Opin Gastroenterol 2009; 25(3): 279-284.
69. Malouf G, Dreyer C, Guedj N et al. Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools. Bull Cancer 2009, 96(4): 405-415.
70. NCCN Practice Guidelines in Oncology [website], Hepatobiliary Cancers. [cited January 5, 2010]. Available from wwwnccn.org
71. Meyer CG, Penn I, James L. Liver transplantation for cholangiocarcinoma: Results in 207 patients. Transplantation 2000; 69(8): 1633-1637.
72. Heneghan MA, Tuttle-Newhall JE, Suhocki PV et al. De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am J Transplant 2003; 3(5): 634-638.
73. Rea DJ, Rosen CB, Nagorney DM et al. Transplantation for cholangiocarcinoma: when and for whom? Surg Oncol Clin N Am 2009; 18(2): 325-337, ix.
74. McMasters KM, Tuttle TM, Leach SD et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 1997; 174(6): 605-608.
75. Freeman ML, Sielaff TD. A modern approach to malignant hilar biliary obstruction. Rev Gastroenterol Disord 2003; 3(4): 187-201.
76. Prat F, Lafon C, De Lima DM et al. Endoscopic treatment of cholangiocarcinoma and carcinoma of the duodenal papilla by intraductal high-intensity US. Results of a pilot study. Gastrointest Endosc 2002; 56(6): 909-915.
77. Burger I, Hong K, Schulick R et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005; 16(3): 353-361.
78. Hidaka H, Kokubu S, Ono K. Radiofrequency ablation. Gan To Kagaku Ryoho 2001; 28(13): 1955-1961.
79. Bachar GN, Greif F, Mor E et al. Radiofrequency ablation for the management of liver tumours. Isr Med Assoc J 2003; 5(7): 496-500.
80. Siperstein A, Garland A, Engle K et al. Laparoscopic radiofrequency ablation of primary and metastatic liver tumours. Technical considerations. Surg Endosc 2000; 14(4): 400-405.
81. Martin R, Jarnagin W. Intrahepatic cholangiocarcinoma. Current management. Minerva Chir 2003; 58(4): 469-478.
82. Jarnagin WR, Ruo L, Little SA et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98(8): 1689-1700.
83. Yalcin S. Diagnosis and management of cholangiocarcinomas a comprehensive review Hepatogastroenterology 2004; 51(55): 43-50.
84. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 2002; 29(6 Suppl 20): 40-45.
85. Hezel AF, Zhu AX Systemic Therapy for Biliary Tract Cancers. Oncologist 2008, 13(4); 415-423.
86. Melichar B, Cerman J Jr, Dvorak J et al. Regional chemotherapy in biliary tract cancers - a single institution experience. Hepatogastroenterology 2002; 49(46): 900-906.
87. Andrýsek O, Horák H, Linhart L et al. Naše výsledky kombinované systémové a intraarteriální chemoterapie jaterních metastáz kolorektálního karcinomu a karcinomu žlučový ch cest. Klin Onkol 1988; 1(4): 98-101.
88. Lersch C, Classen M. Palliative therapy of carcinomas of the biliary system. Med Klin (Munich) 1997; 92(7): 401-405.
89. Bosset JF, Mantion G, Gillet M et al. Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation. Cancer 1989, 64(9): 1843-1847.
90. de Aretxabala X, Roa I, Burgos L et al. Preoperative chemoradiotherapy in the treatment of gallbladder cancer. Am Surg 1999, 65(3): 241-246.
91. Macdonald OK, Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. Surg Oncol Clin N Am 2002; 11(4): 941-954.
92. Czito BG, Anscher MS, Willett CG. Radiation therapy in the treatment of cholangiocarcinoma. Oncology (Williston Park) 2006; 20(8): 873-884.
93. Saito H, Takada T, Miyazaki M et al. Japanese Association of Biliary Surgery; Japanese Society of Hepato-Biliary-Pancreatic Surgery; Japan Society of Clinical Oncology. Radiation therapy and photodynamic therapy for biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 2008; 15(1). 63-8. Epub 2008 Feb 16.
94. Zhai R, Qian X, Dai D et al. Malignant biliary obstruction: treatment with interventional radiology. Chin Med J (Engl) 2003; 116(6): 888-892.
95. Válek V, Kysela P, Kala Z et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol 2007; 62(2): 175-179. Epub 2007 Mar 6.
96. Guo ZJ, Li Q et al Diagnosis and treatment of hepatic cholangiocarcinoma: report of 52 cases. Hepatobiliary Pancreat Dis Int 2003; 2(1): 62-65.
97. Ortner ME, Caca K, Berr F et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125(5): 1536-1538.
98. Berr F, Wiedmann M, Tannapfel A et al. Photodynamic therapy for advanced bile duct cancer, evidence for improved palliation and extended survival. Hepatology 2000; 31(2): 291-298.
99. Ustundag Y, Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J Gastroenterol 2008; 14(42): 6458-6466.